Fig. 5
From: STAT3: Key targets of growth-promoting receptor positive breast cancer
Schematic diagram of action mechanism of STAT3 direct inhibitor. Presently, the treatment strategy for STAT3 inhibitors in breast cancer mainly involves inhibiting the biological function of STAT3 protein directly or by inhibiting the mRNA level of STAT3 protein. A Direct inhibitors of STAT3 mainly target the SH2 or DBD binding domains of STAT3. These inhibitors can inhibit STAT3 transcription by inhibiting STAT3 dimerization or it's binding to DNA. B Some PROTAC drugs (SD-36) mainly degrade STAT3 protein, thus reducing it's expression levels [196]